In the reported cellular replicon panel, BMS-790052 had EC50 values of 50 ± 13 pM for genotype 1a H77 and 9 ± 4 pM for genotype 1b Con1. The Huh-7 cytotoxicity endpoint was 17 ± 1 μM. These are model-specific assay endpoints; the table does not define the meaning of ± or identify a replicate count for these rows. [2]
Direct NS5A binding depends on the protein fragment
Biochemical assay · Isolated HCV genotype 1b (Con1) NS5A domain 1 fragments, residues 33–202 and 26–202. [1]
Microscale thermophoresis detected direct binding to both fragments, with weaker affinity for the longer fragment. These are biochemical dissociation constants, not cellular EC50 values.
Literature-Reported Treatment Conditions
- Method
- Ligand-binding concentration series measured by MST using labelled isolated protein.
- Vehicle
- 5% DMSO in the final MST assay buffer.
- Reported limits
- No treatment dose is implied by KD. Counterion is unspecified. Independent protein preparations are not enumerated; do not equate triplicate curves with biological replicates.
Methods and source locations
Compound reported in the paper: BMS-790052 (daclatasvir); Compound label in the paper: BMS-790052
Results apply to the authors’ BMS-790052 material and specified models; they do not validate an Adooq lot or define salt-specific performance.
Results: NS5A inhibitors bind to domain 1 of NS5A and compete with RNA binding; Figures 2e and 3e; Methods: Materials and MST.
Binding to NS5A residues 33–202: Microscale thermophoresis (MST); reported fitted affinity. Curves determined in triplicate, displayed as mean ± SD. — Figure 2e and caption; Results, NS5A inhibitors bind to domain 1; Methods, MST.
Binding to NS5A residues 26–202: MST; reported fitted affinity. Curves determined in triplicate, displayed as mean ± SD. — Figure 3e and caption; Results, NS5A inhibitors bind to domain 1; Methods, MST.
Reduced RNA affinity in an isolated-protein assay
Biochemical assay · HCV genotype 1b (Con1) NS5A residues 33–202; short single-stranded five-uridine RNA (5rU). [1]
Preincubation with BMS-790052 reduced the measured affinity of the isolated fragment for 5rU. The assay supports a biochemical effect on RNA binding, while the exact binding pose remains a model.
Literature-Reported Treatment Conditions
- Treatment concentration
- 0.25 μM BMS-790052 in the inhibitor-preincubation condition.
- Method
- Comparison of RNA-binding affinity with and without inhibitor preincubation.
- Vehicle
- 5% DMSO in the final MST assay buffer.
- Reported limits
- Preincubation duration is not specified in the read relevant description. A short RNA and truncated protein cannot establish the full cellular mechanism.
Methods and source locations
Compound reported in the paper: BMS-790052 (daclatasvir); Compound label in the paper: BMS-790052
Results apply to the authors’ BMS-790052 material and specified models; they do not validate an Adooq lot or define salt-specific performance.
Figure 2b,i and caption; Results: NS5A inhibitors bind to domain 1 of NS5A and compete with RNA binding; Methods: MST.
5rU binding without inhibitor: MST; triplicate binding curves displayed as mean ± SD. — Figure 2b; Results, In vitro NS5A binding assay; Figure 2 caption.
5rU binding following preincubation with BMS-790052: MST; triplicate binding curves displayed as mean ± SD. — Figure 2i; Results, NS5A inhibitors bind to domain 1; Figure 2 caption.
Cellular potency with a parallel cytotoxicity endpoint
Cell-based study · HCV genotype 1a H77 and genotype 1b Con1 replicon systems; Huh-7 hepatoma-cell cytotoxicity. [2]
BMS-790052 showed picomolar half-maximal inhibition in the two reported replicon models, with a micromolar Huh-7 cytotoxicity endpoint. These assay results are not clinical doses or evidence that every viral genotype responds identically.
Literature-Reported Treatment Conditions
- Method
- Cell-based replication-inhibition and cytotoxicity endpoints. The methods describe FRET and luciferase formats and a DMSO-only viability control.
- Vehicle
- DMSO controls are described for the luciferase/cytotoxicity format; Table 1 does not assign a format to each row.
- Reported limits
- Table 1 does not assign assay format, treatment duration, replicate count or ± definition to each row. The luciferase format specifies a 72 h exposure, but that duration is not assigned here to all table rows. EC50 values are endpoints, not treatment concentrations.
Methods and source locations
Compound reported in the paper: BMS-790052 (daclatasvir); Compound label in the paper: BMS-790052
Results apply to the authors’ BMS-790052 material and specified models; they do not validate an Adooq lot or define salt-specific performance.
Table 1 (genotype 1a H77, genotype 1b Con1 and Huh-7 cytotoxicity rows); opening compound-profile paragraph; Figure 1; Online Methods: Replicon assays (endpoint/control portions).
Genotype 1a H77 replicon inhibition: Cell-based replicon inhibition; original Table 1. The table does not state the replicate count or define ±. — Table 1, HCV replicon genotype 1a, H77 row.
Genotype 1b Con1 replicon inhibition: Cell-based replicon inhibition; original Table 1. The table does not state the replicate count or define ±. — Table 1, HCV replicon genotype 1b, Con1 row.
Half-maximal Huh-7 cytotoxicity endpoint: Table 1 cytotoxicity row; described luciferase-format assay assesses cell viability with CellTiter-Blue and DMSO-only controls. Table 1 groups this row under an EC50 header; the main profile paragraph discusses the CC50/EC50 index. — Table 1, Cytotoxicity Huh-7 cells row; Online Methods, Replicon assays; opening profile paragraph.